Fmr LLC Buys 237,888 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

FMR LLC raised its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 7.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,280,890 shares of the company's stock after purchasing an additional 237,888 shares during the quarter. FMR LLC owned about 2.63% of Henry Schein worth $239,177,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Cromwell Holdings LLC boosted its holdings in shares of Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company's stock valued at $26,000 after acquiring an additional 170 shares in the last quarter. Summit Securities Group LLC acquired a new position in Henry Schein in the 2nd quarter valued at approximately $31,000. Blue Trust Inc. lifted its position in Henry Schein by 104.2% in the 2nd quarter. Blue Trust Inc. now owns 931 shares of the company's stock worth $60,000 after buying an additional 475 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Henry Schein by 58.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 933 shares of the company's stock valued at $68,000 after buying an additional 346 shares during the period. Finally, Mather Group LLC. grew its holdings in shares of Henry Schein by 16.8% during the 2nd quarter. Mather Group LLC. now owns 1,502 shares of the company's stock valued at $96,000 after acquiring an additional 216 shares in the last quarter. Institutional investors own 96.62% of the company's stock.

Henry Schein Trading Down 0.2 %

NASDAQ HSIC traded down $0.17 during trading hours on Monday, hitting $76.88. The company's stock had a trading volume of 528,929 shares, compared to its average volume of 1,393,382. Henry Schein, Inc. has a twelve month low of $63.67 and a twelve month high of $82.63. The firm has a market capitalization of $9.59 billion, a P/E ratio of 31.71, a PEG ratio of 2.21 and a beta of 0.87. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The stock has a fifty day moving average of $71.48 and a 200 day moving average of $69.87.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm's quarterly revenue was up .4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.32 earnings per share. Equities research analysts forecast that Henry Schein, Inc. will post 4.78 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Lorelei Mcglynn sold 21,035 shares of Henry Schein stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $69.30, for a total transaction of $1,457,725.50. Following the completion of the transaction, the senior vice president now owns 71,833 shares in the company, valued at approximately $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Michael S. Ettinger sold 12,240 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the sale, the chief operating officer now owns 87,706 shares of the company's stock, valued at $6,577,950. This trade represents a 12.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on HSIC shares. JPMorgan Chase & Co. dropped their price objective on Henry Schein from $88.00 to $80.00 and set an "overweight" rating on the stock in a report on Monday, August 12th. Barrington Research reissued an "outperform" rating and set a $82.00 target price on shares of Henry Schein in a research report on Wednesday, November 6th. Evercore ISI boosted their price objective on Henry Schein from $70.00 to $74.00 and gave the company an "in-line" rating in a research report on Tuesday, October 8th. Robert W. Baird reduced their target price on Henry Schein from $92.00 to $82.00 and set an "outperform" rating for the company in a research report on Wednesday, August 7th. Finally, UBS Group lowered their price target on shares of Henry Schein from $75.00 to $72.00 and set a "neutral" rating on the stock in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Henry Schein presently has a consensus rating of "Moderate Buy" and an average price target of $79.38.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.